Report Phase 1 Multiple Ascending Dose results for YTX-7739 in healthy volunteers
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“1Q 2021 – Ph 1 MAD in Healthy Volunteers”
What we found
Evidence strength A What the grades mean
The company committed to reporting Phase 1 MAD results in 1Q 2021, but filings confirm the results were announced in April 2021, which is in the second quarter.
-
A Yumanity Therapeutics, Inc. 8-K filed 2021-03-31
“The Company expects to report the results of the Phase 1a part of the MAD study of YTX-7739 in healthy volunteers in the beginning of the second quarter of 2021.” ✓ confirmed on the page
-
A Yumanity Therapeutics, Inc. 10-Q filed 2021-05-13
“We also completed a Phase 1a multiple ascending dose (“MAD”) study in healthy volunteers, and announced results in April 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 1 MAD results for YTX-7739
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Yumanity Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C445283-021529 · Corrections policy